48 results about "Viral rna" patented technology

This invention generally relates to a novel RNA / mRNA production and amplification method using viral RNA replicase and / or RNA-dependent RNA polymerase (RdRp) enzymes as well as the associated mRNAs thereof. The present invention can be used for manufacturing and amplifying all varieties of RNA / mRNA sequences carrying at least an RdRp-binding site in the 5′- or 3′-end, or both. The RNA / mRNA so obtained is useful for not only producing mRNA vaccines and / or RNA-based medicines but also for generating the mRNA-associated proteins, peptides, and / or antibodies under an in-vitro as well as in-cell translation condition. Principally, the present invention is a novel RNA replicase-mediated RNA / mRNA amplification method, namely Replicase Cycling Reaction (RCR). The RNA replicases involved in RCR include but not limited to viral and / or bacteriophage RNA-dependent RNA polymerases (RdRp), particularly coronaviral and hepatitis C viral (HCV) RdRp enzymes.

The present inventors have conducted intensive studies on an antibody which controls HIV in an administration group with a high probability over a long period of time with one or several times of single-agent administration. As a result, the present inventors have surprisingly found that, when an SW-1C10 antibody, which is obtained by producing an antibody gene reported as 1C10 in silkworms, is singly administered only a few times, the viral load in the blood is suppressed to the detection limit or lower at an early stage in all of individuals to which the antibody has been administered, and moreover, the viral RNA load in the blood is maintained at the detection limit or lower for a long time of 12 weeks.

The invention discloses an influenza reporter virus carrying a fluorescent RNA aptamer and a construction method and application thereof, and the influenza reporter virus carrying the fluorescent RNA aptamer is obtained by introducing a termination codon TAA into the 328th nucleotide of an ORF region of an NS1 gene on the basis of a genome of an influenza A virus and terminating in advance, then introducing a terminating codon TAA into the 328th nucleotide of the ORF region of the NS1 gene of the influenza A virus; original nucleotides at the 328-480 sites are replaced by forward or reverse RNA aptamers, and the RNA aptamer is obtained. The influenza reporter virus carrying the fluorescent RNA aptamer constructed by the invention also has the characteristics of good virus replication ability, high RNA imaging sensitivity and good specificity on the basis of stable inheritance, can be used for real-time visual observation of virus RNA, and is used for research on virus replication cycle and molecular mechanism related to the virus RNA. Besides, the construction method of the influenza reporter virus carrying the fluorescent RNA aptamer can also be applied to construction of RNA fluorescent reporter viruses of other subtype influenza viruses such as H3N2 and H5N1, and an important tool is provided for real-time tracing of corresponding virus RNA.

A protection method, a protection sequence, a composition and a kit for preventing RNA degradation, and the use thereof, which can improve the protective effect on viral RNA. After the protection sequence RNase AP is added, the three-dimensional structure of RNA and the structural allosteric characteristics of RNA can be protected; and the protection sequence has a good protection effect on RNA integrity, and a high-level detection rate can be obtained by a one-time amplification, thereby ensuring efficient enrichment of viral RNA and providing guarantee for subsequent reverse transcription and PCR amplification.

Methods of inhibiting a respiratory virus, (i.e., a virus associated with a respiratory condition, e.g., influenza A, influenza B, RSV, etc.) in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a target motif with an effective amount of an agent that specifically binds the target motif to inhibit the respiratory virus. Also provided are methods of treating or preventing respiratory virus infection in a subject. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a target vRNA region that find use in the subject methods.

The invention relates to an infectious arenavirus particle that is genetically engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but incapable of producing further infectious progeny particles in normal, non-genetically engineered cells.One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z, and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells, but still allow gene expression in arenavirus vector-infected cells, and foreign genes encoding an antigen or other protein of interest or nucleic acids that regulate host gene expression are expressed under the control of arenavirus promoters, internal ribosome entry sites, or under the control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II, or RNA polymerase III. The modified arenaviruses are useful as vaccines and therapeutic agents for a variety of diseases.

The application discloses a kind of RNA virus nucleic acid preservative in fecal sample, including denaturant, chelating agent, pH buffering agent, osmotic pressure regulator and reducing agent;The denaturant includes guanidine salt and surfactant;The application further additionally provides a kind of RNA virus nucleic acid preservative in fecal sample preparation method, preparation above-mentioned one kind of RNA virus nucleic acid preservative in fecal sample, including the following steps: each component is mixed with ratio, pH is adjusted with pH buffering agent, with deionized water constant volume;Filter, obtain the preservative solution described in this application.The preservative solution of the application can stably store human cell DNA and viral RNA in fecal sample at room temperature for at least 7 days, which is beneficial for long-distance transportation at room temperature;Meanwhile, the preservative solution of the application also releases nucleic acid, inactivates virus, so as to prevent biological leakage and infection phenomenon;The de-inhibitor component in the preservative solution can directly combine and precipitate with various inhibitors in feces, reducing the interference to nucleic acid detection.

The invention discloses application of nicotinamide ribose (NR) in preparation of anti-influenza virus products, and belongs to the technical field of biotechnology and medicine. The NR is used as a human endogenous metabolite, has excellent safety, activates SIRT1 by increasing the NAD + level in cells, and further inhibits influenza virus NP protein nucleus input and virus RNA synthesis. Experiments prove that NR has a remarkable inhibition effect on replication of various subtype influenza A viruses such as H1N1, H9N2 and H3N2, still has an inhibition effect under high-MOI infection, has a good use effect at the early stage of infection, and provides a new choice for anti-influenza virus drugs.

The invention discloses lactobacillus mucosa with porcine virus resisting activity and application of the lactobacillus mucosa, and relates to the technical field of microorganism application and virus prevention and control. It is found for the first time that the lactobacillus mucosa has broad-spectrum antiviral activity, not only has a remarkable inhibition effect on porcine reproductive and respiratory syndrome virus type 2 (PRRSV2) strains, but also can further resist porcine epidemic diarrhea virus (PEDV) and porcine rotavirus (PoRV); according to the present invention, the Lactobacillus mucosa is adopted to culture the supernatant, such that the supernatant does not have toxicity on Marc-145 cells; according to the PRRSV2 strain treated by using the supernatant, the expression level of virus RNA and protein and the filial generation virus titer are remarkably reduced, so that the infection ability is weakened; the culture supernatant directly acts with virus particles to block infection and replication of the virus particles; the product disclosed by the invention is derived from natural probiotics, is high in safety, environment-friendly and not easy to resist drugs, can be used for preparing a broad-spectrum anti-porcine virus biological preparation, provides a new strategy for preventing and controlling porcine virus diseases, and has a good industrial application prospect.

A method and composition for the simultaneous detection of a protein and a nucleic acid within a single biological sample using proximity ligation of aptamers and quantitative polymerase chain reaction (qPCR) is disclosed. The invention employs two aptamers, each targeting a distinct epitope of the protein of interest, functionalized with primer sites to enable ligation by way of a short DNA linker in the presence of the protein. This ligated construct is then amplified and detected using qPCR. Concurrently, viral RNA is detected in the same reaction using reverse transcription- qPCR (RT-qPCR) with TaqMan probes in a separate fluorescent channel. This dual detection approach is demonstrated with SARS-CoV-2 nucleocapsid protein and RNA and is validated in saliva samples and digital droplet PCR. The invention provides a sensitive, rapid, and specific method for multiplexed molecular diagnostics.

This invention belongs to the field of biomedical technology, specifically disclosing a scorpion-derived polypeptide for combating influenza virus and its applications. The scorpion-derived polypeptide has the amino acid sequence shown in SEQ ID NO:1, or is a functional variant obtained by substitution, deletion, and / or addition of one or more amino acids from the same sequence, retaining its anti-influenza virus activity. The scorpion-derived polypeptide provided by this invention can significantly inhibit the proliferation of influenza A virus and substantially reduce the expression levels of viral RNA and protein within a non-cytotoxic concentration range. It also effectively reduces viral load and inflammatory factor levels in mice infected with influenza A virus, exhibiting excellent anti-influenza A virus activity and being less likely to induce viral resistance. This invention provides a novel, highly efficient, and low-toxicity bioactive molecule for influenza prevention and control, which can be applied to the development of anti-influenza drugs.

The application provides a phosphoramidate morpholino antisense oligonucleotide for antiviral, which comprises a base sequence shown as SEQ ID NO. 1, the antisense oligonucleotide is a phosphoramidate morpholino antisense oligonucleotide, the structural formula of the phosphoramidate morpholino nucleotide monomer in the antisense oligonucleotide is shown in the following formula, Base is a base; R is N, N-dimethylamine or piperazine. The antisense oligonucleotide can be combined with a specific region in the fifth segment of viral RNA of an influenza virus, block the transcription of the viral RNA through steric hindrance, play an antiviral role, and use a PMO structure which is good in nuclease stability, high in antisense efficiency and good in water solubility, and at the same time, by introducing a piperazine group which is positively charged under physiological conditions, the PMO compound can enter the cell across the membrane, and the biological activity of the compound can be effectively enhanced.

The present invention provides methods and kits for detecting and quantifying the presence of porcine virus PERV-A, PERV-B, PCMV, PCV3, PLHV-1, PLHV-2, and PLHV-3 nucleic acids in a sample from a xenotransplant subject that has received cells, tissues or an organ from a pig.

This invention discloses a drug for preventing and treating myocarditis caused by CVB3 virus and its application, belonging to the field of biomedical technology. This invention discovers an hsa-miR-199a-5p mimic that can be used to prevent and treat myocarditis caused by CVB3 virus. The nucleotide sequence of this hsa-miR-199a-5p mimic is shown in SEQ ID NO.1, and its antisense strand nucleotide sequence is shown in SEQ ID NO.2. This invention reveals that hsa-miR-199a-5p mimics can effectively inhibit viral RNA replication and protein biosynthesis and expression in CVB3, and reduce cell death caused by viral infection. Therefore, hsa-miR-199a-5p plays an important role in regulating and controlling CVB3 replication and protein expression. The use of hsa-miR-199a-5p mimics and / or their antisense strands to prepare anti-CVB3 virus drugs, drugs for the prevention and / or treatment of viral myocarditis, drugs for inhibiting CVB3 viral protein expression, drugs for inhibiting CVB3 viral replication, or drugs for reducing CVB3 virus-induced cell death, as well as the preparation of CVB3 virus detection products and viral myocarditis diagnostic products, all have significant clinical application potential.

Type-C endogenous retroviruses (ERVs) embedded in Chinese hamster ovary (CHO) cells were altered to modify the release of retroviral and / or retroviral-like particles in the culture supernatant. Although evidence for the infectivity of these particles is missing. their presence has raised safety concerns. 173 type-C ERV sequences that clustered into functionally conserved groups were identified. Transcripts from one type-C ERV group were identified to be full-length with intact open reading frames, and to have corresponding viral RNA genomes that were loaded into retroviral-like particles. Also, sequence analysis of the genomic RNA from viral particles indicated that they may result from few expressed ERV sequences. Disclosed herein is the disruption / alteration of the gag gene of the expressed ERV group using CRISPR-Cas9 genome editing. Comparison of CRISPR-derived mutations at the DNA and mRNA level led to the identification of a single ERV locus responsible for the release of viral RNA-loaded particles from CHO cells. Clones bearing a Gag loss-of-function mutation in this particular ERV locus showed a reduction of viral RNA-containing particles in the cell supernatant by over 250-fold. Notably, ERV mutagenesis did not compromise cell growth, cell size or recombinant protein production. Provided herein is a new strategy and cells, in particular engineered CHO cells, to mitigate potential contaminations from CHO endogenous retroviruses during biopharmaceutical manufacturing.

The application discloses a chimera specifically targeting and degrading an RNA virus genome and an application thereof, and the chimera is composed of a chimera N and a chimera C; the chimera N is sequentially connected with a MAVS CARD domain, a connecting peptide and an N terminal of RNase A; the chimera C is sequentially connected with a MAVS CARD domain, a connecting peptide and a C terminal of RNase A; and the N terminal of RNase A and the C terminal of RNase A are obtained by segmenting RNase A at a segmentation site. The chimera in the application assembles in situ to form a CARTAC complex with RNA cleavage activity, and then degrades a viral RNA genome, thereby providing a safe, broad-spectrum and effective prevention and treatment strategy for resisting RNA virus infection.

Provided are compositions, systems, and methods useful for effecting gene editing in eukaryotic cells. Compositions include plasmids that encode one or more viral fusion proteins in which one or more viral proteins are fused with an aptamer-binding protein. Compositions also include plasmids that encode a non-viral nucleic acid sequence, wherein the non-viral nucleic acid sequence encodes a CRISPR system component. In some instances, the non-viral nucleic acid sequence also includes an aptamer sequence. The plasmids can be used to generate viral particles, including lentivirus-like particles that contain a viral fusion protein and a non-viral RNA sequence. Systems of producing such viral particles are provided. Also provided are methods of using the viral particles of the disclosure to effect gene editing in eukaryotic cells.

The invention relates to an anti-dengue virus medicine containing a ferroptosis inhibitor and application of the anti-dengue virus medicine, in particular to medical application of the ferroptosis inhibitor in resisting dengue virus infection. In-vitro experiments prove that DENV infection can activate a host cell ferroptosis pathway; after 1-3 [mu] M of Ferrostatin-1 or Liproxstatin-1 is adopted for intervention, the activation of the pathway can be effectively inhibited, and the virus RNA replication and protein expression level can be remarkably reduced. According to the technical scheme, the existing activity of the known ferroptosis inhibitor is utilized, new indications for resisting DENV infection of the ferroptosis inhibitor are developed, a candidate drug strategy of a targeted ferroptosis pathway is provided for dengue treatment, the technical problem that the action target of an existing antiviral drug is limited is solved, and the obvious clinical application and development value is achieved.

The present invention relates to a polypeptide composition, comprising a nucleic acid encoding a mutant pp65 polypeptide, the nucleic acid being mRNA, viral RNA, or replicon RNA. The composition is capable of expressing the mutant pp65 polypeptide in vivo, eliciting a specific humoral or cellular immune response against the pp65 polypeptide, and producing an effector cell having a tumor cell killing effect and a specific antibody.

Methods of inhibiting influenza A virus in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a PSL2 motif with an effective amount of an agent that specifically binds the PSL2 motif to inhibit the influenza A virus. Also provided are methods of treating or preventing influenza A virus infection in a subject. Also provided are methods for screening a candidate agent for the ability to inhibit influenza A virus in a cell, the method comprising: contacting a sample with a candidate agent; and determining whether the candidate agent specifically binds to the PSL2 motif of vRNA. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a PB2 vRNA region that find use in the subject methods.

This invention discloses the application of bufotoxin lactones in the preparation of anti-IHNV products, belonging to the field of biomedical technology. This invention is the first to discover and confirm that four bufotalin-based drugs (bufotalin, bufotalin ester, bufotalin, and bufotalin) have significant anti-IHNV effects: their IC50 values ​​against IHNV in vitro range from 0.0879 to 0.1809 μM, with selectivity indices all greater than 110. After 48 hours of treatment, they can reduce viral RNA expression by 110 to 173 times and viral titer by 4.36 to 5.15 lg; they also show broad-spectrum inhibitory effects against different genotypes of IHNV, such as LN-15, QH-17, and Blk94; in a rainbow trout in vivo model, after administration of a 0.5 mg / kg dose, the cumulative mortality rate decreased from 95% in the control group to 13.3% to 21.7%, with the highest relative protection rate reaching 85.96% (bufotalin), indicating that these compounds have highly efficient, broad-spectrum, and low-toxicity anti-IHNV activity and have excellent application prospects.

The invention discloses a chimera capable of specifically degrading an RNA (Ribonucleic Acid) virus genome in a targeted manner and application of the chimera. The chimera consists of a chimera N and a chimera C, the chimera N is formed by connecting an MAVS CARD structural domain, a connecting peptide and the N end of RNase A in sequence; the chimera C is formed by connecting an MAVS CARD structural domain, a connecting peptide and the C end of RNase A in sequence; the N end of the RNase A and the C end of the RNase A are obtained by segmenting the RNase A at a segmentation site. The chimera disclosed by the invention is assembled in situ to form a CARTAC compound with RNA cleavage activity, so that a virus RNA genome is degraded, and a safe, broad-spectrum and effective prevention and treatment strategy is provided for resisting RNA virus infection.

Methods for inhibiting respiratory viruses (i.e., viruses associated with respiratory conditions, e.g., influenza A, influenza B, RSV, and the like) are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a target motif with an effective amount of an agent that specifically binds to the target motif to inhibit the respiratory virus. Methods for treating or preventing respiratory virus infection in a subject are also provided. Pharmaceutical compounds and compositions comprising an oligonucleotide sequence complementary to a target region of the vRNA used in the methods are also provided. The oligonucleotides provided may include a 5-methylcytosine.

This invention belongs to the fields of bioinformatics and protein function identification, specifically relating to a machine learning-based method for identifying viral RNA silencing repressors. The method includes: obtaining the amino acid sequence of the viral protein to be tested, inputting it into a pre-trained ESM-2 model to extract deep feature vectors, then inputting the feature vectors into a trained XGBoost classifier, and outputting an identification result indicating whether the viral protein is a viral RNA silencing repressor. This invention integrates the automatic feature extraction capability of ESM-2 with the efficient classification performance of XGBoost, significantly improving prediction accuracy and generalization ability. It is mainly used in fields such as plant antiviral genetic engineering, disease-resistant breeding, and biopesticide development, enabling rapid screening of potential viral RNA silencing repressors and providing an efficient tool for functional gene mining.

Silica-coated magnetic nanoparticles with greater ability to remain dispersed, and methods of making and using silica-coated magnetic nanoparticles, including incubation of an aqueous dispersion of newly made particles at room temperature for a time period resulting in clusters of silica-coated magnetic nanoparticles, the resulting clusters being of an optimal size for viral RNA extraction from human clinical samples. The magnetic nanoparticles comprise a core and a coating, where the core comprises Fe3O4 or other magnetic material and the coating has a thickness of from about 1.5 nm to about 2 nm. The magnetic nanoparticles are useful for preparing nucleic acids for analysis, by separating nucleic acids from other components and by normalizing nucleic acid concentrations.

Provided herein are nucleoside analogs and nucleotide analogs for suppressing virus proliferation in a cell, or for suppressing a viral infection in a patient in need thereof. Also provided herein are methods of use. The nucleoside analogs disclosed herein are converted to nucleotide analogs by phosphorylation. Nucleotide analogs are incorporated into elongating nucleic acid chains, causing elongation to terminate, thereby inhibiting viral nucleic acid synthesis.

A nucleic acid molecule in the form of a plasmid comprising an origin of replication, a promoter for the transcription into viral RNA; a 3'NCT triplet upstream of regions for the insertion of gene(s) of interest, separated by Measles virus intergenic regions, and one 5'NCT sharing at least 95% of identity with SEQ ID NO: 11 over its full-length, wherein the 3'NCT triplet shares at least 95% of identity with SEQ ID NO:14 over its full-length, the corresponding helper nucleic acid molecules, a process for the production of virosomes based on these nucleic acid based molecules, the obtained virosomes and their therapeutical uses.

The application discloses siRNA for inhibiting bata virus replication, an RNA delivery system and application thereof, and relates to the technical field of nucleic acid drugs and antiviral treatment. The siRNA is designed according to a conserved region of an S segment of SFTSV, and the siRNA can not only target the S segment of different strains of SFTSV, but also target the S segment of other bata viruses. In a cell model, the siRNA can reduce the viral RNA level, viral protein expression and viral titer, thereby inhibiting bata virus replication. In addition, the application further provides an RNA delivery system, which can realize effective in-vivo delivery of the siRNA and enhance the antiviral effect. Therefore, the siRNA provided by the application is expected to be used for prevention or treatment of SFTSV and other bata virus infections.

The present invention relates to a polypeptide composition comprising a nucleic acid encoding a mutated pp65 polypeptide, the nucleic acid being mRNA, viral RNA or replicon RNA, said composition being capable of expressing the mutated pp65 polypeptide in vivo, eliciting a specific humoral or cellular immune response against the pp65 polypeptide, producing effector cells and specific antibodies having a tumor cell killing effect.